Fingenious®

The #GenomeHealth project is an excellent example of how #biobank studies can promote personalized medicine and how genomic information produced in biobank research projects can be utilized in healthcare for the benefit of the patient. FINBB’s Fingenious® digital service called #MyBiobank was utilized in GenomeHealth project to facilitate information sharing and to collect approvals from research participants for the analysis and return of genetic results from their biobank samples. The GenomeHealth project is a national initiative carried out by all six Finnish hospital biobanks and funded by a state grant from the Ministry of Social Affairs and Health between 2021-2023. In the project high-risk cancer susceptibility gene defects in BRCA1, BRCA2, and PALB2, were screened (based on genotyping data returned from FinnGen) and validated from over 200 000 biobank samples. Using a specifically developed healthcare process, genomic risk information was returned to biobank donors when they had consented to that. This enabled informed decisions, personalized care and even preventive action. As part of the GenomeHealth project, a cost-effectiveness analysis of the effects of returning genomic results produced in biobank operations was carried out by ESiOR Oy, funded by the Finnish Biobank Cooperative FINBB. Find out more at: https://lnkd.in/d4VjtGGk #MyBiobank #GenomeHealth #Fingenious

Did you know that the Finnish Biobank Act allows Finnish biobanks to contact consented sample donors based on genotype and phenotype, and invite them to participate in biomedical studies? 95% of the biobank consented individuals have given a consent to be recontacted. A digital platform called #MyBiobank has been launched by Finnish Biobank Cooperative – FINBB together with Finnish #biobanks, hospital districts and the #FinnGen research project. The goal of MyBiobank is to provide a versatile and secure online platform for easy contacting of biobank sample donors and to facilitate electronic communication between donors, biobanks and researchers. MyBiobank can be used to contact potential study participants for clinical studies, to gather patient reported outcomes (PROs) and questionnaires, and also to return data to study participants. Read more at https://lnkd.in/dMmeejhB #biomedicalresearch #Fingenious #MyBiobank #biobanks #FinnGen

Join the symposium on Sep 30th where Amy Jones will share an interesting ophthalmology research collaboration by Gyroscope Therapeutics and Finnish Biobanks in investigating genetic variant prevalences and how this helped clinical development of a novel gene therapy for dry age-related macular degeneration (AMD). Explore symposium programme and register here! https://lnkd.in/d7HX-wKV Symposium: From Target Discovery to Precision Medicine - the Unique Potential of Finnish Biobanks in Biomedical Research Amy Jones is a biopharma professional with over 20 years of experience in industry, biotechnology, clinical, and academic roles, including seven years in bio-therapeutic development. In 2019, Amy joined Gyroscope Therapeutics to lead a targeted genetics strategy for the clinical development of GT005, a complement factor I retinal gene therapy aimed at slowing the progression of dry age-related macular degeneration, which was tested in phase I/II clinical trials. After Gyroscope was acquired by Novartis in 2022, Amy was appointed Head of Genetics Strategy and Innovation. In this role, she expanded her focus to include biomarker strategy for complement assets in Ophthalmology and supported other genetics initiatives. More information on symposium website: https://lnkd.in/d7HX-wKV Welcome to the symposium on 30th Sept 2024 at - 17:30 EET / - 4.30pm CET / - 11.30m ET, US. The symposium is organized by FINBB – Finnish Biobanks and Fingenious® that serves as your digital gateway to Finnish #biobanks and biomedical research. #biomedicalresearch #Fingenious

FINBB – Finnish Biobanks and Fingenious® welcome You to the Symposium on 30th Sept 2024 at 17:30 EET/ 4.30 pm CET/ 11.30 am ET, US. Explore the programme and register: https://lnkd.in/d7HX-wKV Join us online or on-site for interesting #biomedical research cases that span from target discovery to personalized medicine in action, elucidating the research opportunities that Finnish #biobanks and the unique genetic heritage of Finns provide. The symposium brings together professionals from pharma, biotech, and academia from all over the world and offers a spectrum of real-life research examples in oncology, neurology, immunology, ophthalmology, and rare diseases. #biomedicalresearch #Fingenious 

Did you know that Finnish personal ID codes enable comprehensive data linkage from healthcare databases, population-based registers and biobanks. Read more from our website!

The Fingenious® Ecosystem together at Oriola, looking forward to taking our collaboration to the next level! #Fingenious #RWEstudies #biomedicalresearch

Contact us and find the right partner for your RWE needs. Fingenious® Ecosystem – the top expertise of Finnish RWE service providers in one place. Read more: https://lnkd.in/dWTvj3D5

Finnish biobanks – FINBB are exploring new Fingenious®collaboration opportunities! Last week we had a pleasure to meet Prof. Leroy Hood and Dr. Jennifer Lovejoy together with experts from Tampere University to discuss the potential for a novel, exciting collaboration. More to come! #fingenious #research

Finland is leading the way.

Population-wide registry data, world-class services and technology for your RWE research – All in one place! Contact the Fingenious ® Ecosystem.